PALO
ALTO, Calif., Nov. 21,
2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq:
KOD), a biopharmaceutical company committed to researching,
developing and commercializing transformative therapeutics to treat
high prevalence retinal diseases, announced today that management
will present at the 6th Annual Evercore ISI HealthCONx
Conference in Miami, Florida on
Wednesday, November 29, 2023, at
3:25 p.m. Eastern Time (12:25 p.m. Pacific Time).
A live webcast of the presentation will be available on the
"Events and Presentations" section of Kodiak's website
at http://ir.kodiak.com/ and will remain available for replay
for a limited time following the event.
About Kodiak Sciences
Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high-prevalence retinal diseases. We are
focused on bringing new science to the design and manufacture of
next generation retinal medicines to prevent and treat the leading
causes of blindness globally. Our antibody biopolymer conjugate
platform, or ABC Platform™, is at the core of Kodiak's discovery
engine. Kodiak's first investigational medicine, tarcocimab
tedromer, is a novel anti-VEGF antibody biopolymer conjugate
explored for the treatment of retinal vascular diseases. Kodiak's
second clinical program, KSI-501, built from a first-in-class
bispecific protein targeting both IL-6 (anti-IL-6 antibody) and
VEGF (VEGF-trap), is intended to treat both orphan and high
prevalence retinal diseases. Kodiak is based in Palo Alto, CA. For more information, please
visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak Sciences
Inc. in various global jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-6th-annual-evercore-isi-healthconx-conference-301995217.html
SOURCE Kodiak Sciences Inc.